{"id":"dexamethasone-or-equivalent","safety":{"commonSideEffects":[{"rate":"10–30%","effect":"Hyperglycemia"},{"rate":"10–20%","effect":"Insomnia"},{"rate":"10–20%","effect":"Increased appetite"},{"rate":"5–15%","effect":"Mood changes (euphoria, anxiety, depression)"},{"rate":"5–10%","effect":"Hypertension"},{"rate":"variable","effect":"Immunosuppression / increased infection risk"},{"rate":"variable","effect":"Osteoporosis (with chronic use)"},{"rate":"5–10%","effect":"Gastrointestinal upset"},{"rate":"5–10%","effect":"Acne"},{"rate":"5–10%","effect":"Fluid retention / edema"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexamethasone enters cells and binds to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene transcription. This leads to decreased production of pro-inflammatory cytokines, reduced immune cell activation and proliferation, and suppression of inflammatory responses. It is approximately 25–30 times more potent than the natural glucocorticoid cortisol.","oneSentence":"Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:15.262Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis)"},{"name":"Cerebral edema and increased intracranial pressure"},{"name":"Adrenocortical insufficiency"},{"name":"Severe allergic reactions"},{"name":"Certain hematologic malignancies (as adjunctive therapy)"},{"name":"Prevention of chemotherapy-induced nausea and vomiting"}]},"trialDetails":[{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":"Triple Negative Breast Neoplasms","enrollment":1000},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT06305754","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-11","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":520},{"nctId":"NCT06824467","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-09","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":770},{"nctId":"NCT06312137","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-03","conditions":"Non Small Cell Lung Cancer","enrollment":780},{"nctId":"NCT07318558","phase":"PHASE3","title":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-02-16","conditions":"Ovarian Neoplasms, Ovarian Cancer","enrollment":900},{"nctId":"NCT06170788","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-15","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":614},{"nctId":"NCT06393374","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-24","conditions":"Triple-Negative Breast Cancer","enrollment":1530},{"nctId":"NCT05319730","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-05-16","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":230},{"nctId":"NCT07216703","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-19","conditions":"Cervical Cancer","enrollment":1023},{"nctId":"NCT07476235","phase":"","title":"Predictors of Treatment Response to Stellate Ganglion Block in Cervical Radicular Pain","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2024-10-08","conditions":"Radiculopathy, Cervical Region","enrollment":90},{"nctId":"NCT06445972","phase":"PHASE1, PHASE2","title":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-08-07","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":210},{"nctId":"NCT07286149","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-23","conditions":"Lung Neoplasm Malignant","enrollment":190},{"nctId":"NCT04488081","phase":"PHASE2","title":"I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2020-07-31","conditions":"COVID-19","enrollment":1500},{"nctId":"NCT07340463","phase":"PHASE2","title":"The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment","status":"RECRUITING","sponsor":"Nanjing University School of Medicine","startDate":"2025-12-08","conditions":"Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)","enrollment":50},{"nctId":"NCT05751187","phase":"PHASE2","title":"Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2023-06-27","conditions":"Non-squamous NSCLC","enrollment":54},{"nctId":"NCT06788912","phase":"PHASE2","title":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Lung Neoplasm Malignant","enrollment":60},{"nctId":"NCT07461727","phase":"PHASE1","title":"An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-10","conditions":"Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Liver Metastases","enrollment":15},{"nctId":"NCT06356311","phase":"PHASE3","title":"A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-03","conditions":"Gastroesophageal Cancer","enrollment":450},{"nctId":"NCT06356571","phase":"PHASE2","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-03-17","conditions":"Plasma Cell Myeloma Refractory","enrollment":64},{"nctId":"NCT06637423","phase":"PHASE1, PHASE2","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-20","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":32},{"nctId":"NCT07419295","phase":"PHASE3","title":"A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-17","conditions":"Bladder Cancer","enrollment":590},{"nctId":"NCT06835387","phase":"PHASE2","title":"Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors","status":"RECRUITING","sponsor":"Tiago Biachi de Castria","startDate":"2025-06-30","conditions":"Small Bowel Adenocarcinoma","enrollment":36},{"nctId":"NCT06074588","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-11-12","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":556},{"nctId":"NCT04743661","phase":"PHASE2","title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2022-04-04","conditions":"Recurrent Medulloblastoma, Recurrent Ependymoma","enrollment":62},{"nctId":"NCT07385131","phase":"","title":"Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-10-08","conditions":"Inflammatory Bowel Disease (IBD), CD - Crohn's Disease, UC - Ulcerative Colitis","enrollment":300},{"nctId":"NCT06428409","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-20","conditions":"Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer","enrollment":220},{"nctId":"NCT07334379","phase":"PHASE2","title":"Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study","status":"RECRUITING","sponsor":"Lorenzo delSorbo","startDate":"2025-10-20","conditions":"Acute Hypoxemic Respiratory Failure","enrollment":60},{"nctId":"NCT03571321","phase":"PHASE1","title":"Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2019-05-28","conditions":"Acute Lymphoblastic Leukemia, ALL, Childhood, ALL","enrollment":15},{"nctId":"NCT06132958","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-06","conditions":"Endometrial Cancer","enrollment":710},{"nctId":"NCT06460961","phase":"PHASE1","title":"A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-14","conditions":"Neoplasm Metastasis","enrollment":168},{"nctId":"NCT04270409","phase":"PHASE3","title":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2020-06-16","conditions":"Plasma Cell Myeloma","enrollment":337},{"nctId":"NCT07169890","phase":"NA","title":"Clinical Insights Into Dextrose Phonophoresis on Mild to Moderate Acne Vulgaris","status":"COMPLETED","sponsor":"MTI University","startDate":"2025-11-01","conditions":"Acne Vulgaris","enrollment":115},{"nctId":"NCT06645678","phase":"PHASE1, PHASE2","title":"Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"YOUNGIL KOH","startDate":"2024-11-26","conditions":"Relapsed Refractory Multiple Myeloma (RRMM)","enrollment":75},{"nctId":"NCT04817189","phase":"PHASE4","title":"Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2021-02-01","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":414},{"nctId":"NCT07052201","phase":"PHASE3","title":"Dexamethasone Regimens for BPD Prevention in Preterm Infants","status":"NOT_YET_RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2026-02-01","conditions":"Infant, Premature, Bronchopulmonary Dysplasia (BPD)","enrollment":970},{"nctId":"NCT05405166","phase":"PHASE3","title":"SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-06-23","conditions":"Plasma Cell Myeloma Recurrent","enrollment":531},{"nctId":"NCT04843761","phase":"PHASE3","title":"ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-20","conditions":"Covid19","enrollment":473},{"nctId":"NCT04606264","phase":"PHASE3","title":"Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data","status":"COMPLETED","sponsor":"Jennifer Holder-Murray","startDate":"2023-05-15","conditions":"Perioperative Optimization","enrollment":2977},{"nctId":"NCT07164677","phase":"NA","title":"Serratus Posterior Superior Plane Block for Postoperative Pain in Cardiac Surgery","status":"RECRUITING","sponsor":"Ondokuz Mayıs University","startDate":"2025-09-13","conditions":"Cardiac Surgery, Post Operative Pain, Acute","enrollment":50},{"nctId":"NCT03860844","phase":"PHASE2","title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":67},{"nctId":"NCT04191616","phase":"PHASE2","title":"Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet","status":"COMPLETED","sponsor":"Amgen","startDate":"2020-08-06","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":54},{"nctId":"NCT06446245","phase":"PHASE2","title":"Adjunctive Doxycycline for Central Nervous System Tuberculosis","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-08-21","conditions":"Tuberculosis, Meningeal, Tuberculosis; Meningitis (Etiology), Tuberculosis, Central Nervous System","enrollment":200},{"nctId":"NCT06023641","phase":"PHASE2","title":"Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-13","conditions":"Rhabdomyosarcoma","enrollment":135},{"nctId":"NCT07109284","phase":"PHASE2","title":"SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2025-09","conditions":"ER+HER2- Breast Cancer","enrollment":55},{"nctId":"NCT06930105","phase":"PHASE2","title":"Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL","status":"NOT_YET_RECRUITING","sponsor":"Xianmin Song, MD","startDate":"2025-09-01","conditions":"Acute Lymphoid Leukemia (ALL)","enrollment":45},{"nctId":"NCT06520345","phase":"PHASE3","title":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2024-07-26","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":430},{"nctId":"NCT05521087","phase":"PHASE1","title":"A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2025-12-26","conditions":"Acute Leukemias, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia","enrollment":""},{"nctId":"NCT02076009","phase":"PHASE3","title":"A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-07-23","conditions":"Multiple Myeloma","enrollment":569},{"nctId":"NCT01998971","phase":"PHASE1","title":"A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02-18","conditions":"Multiple Myeloma","enrollment":240},{"nctId":"NCT05403359","phase":"","title":"StEroids in hospitaLized patiEnts With Covid-19 in The Netherlands.","status":"COMPLETED","sponsor":"Henrik Endeman","startDate":"2022-06-01","conditions":"COVID-19","enrollment":2465},{"nctId":"NCT05635227","phase":"NA","title":"Dexamethasone, Olanzapine, Hemodynamics, and Ventilation in Cardiac Surgery","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2022-11-10","conditions":"Coronary Artery Disease, Aortic Valve Disease","enrollment":1200},{"nctId":"NCT04786964","phase":"PHASE3","title":"Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC","status":"TERMINATED","sponsor":"Checkpoint Therapeutics, Inc.","startDate":"2021-12-08","conditions":"Metastatic Non-squamous Non Small Cell Lung Cancer","enrollment":25},{"nctId":"NCT05707156","phase":"","title":"Prospective Observational Study on the Incidence of Opportunistic Fungal Infections","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2023-07-05","conditions":"Pneumocystis Jirovecii Infection, Pneumocystis, Cryptococcosis","enrollment":12032},{"nctId":"NCT03544281","phase":"PHASE1, PHASE2","title":"To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-09-20","conditions":"Multiple Myeloma","enrollment":153},{"nctId":"NCT05401812","phase":"PHASE2","title":"Glucocorticoid Therapy for Acute Respiratory Distress Syndrome","status":"WITHDRAWN","sponsor":"National Taiwan University Hospital","startDate":"2022-07-01","conditions":"Acute Respiratory Distress Syndrome","enrollment":""},{"nctId":"NCT06766825","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults with Post-COVID-19 Condition (PCC)","status":"RECRUITING","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2025-02-07","conditions":"Post COVID-19 Condition, Long COVID Syndrome, Persistent COVID-19","enrollment":90},{"nctId":"NCT02990338","phase":"PHASE3","title":"Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-12-22","conditions":"Plasma Cell Myeloma","enrollment":307},{"nctId":"NCT03836014","phase":"PHASE3","title":"Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-07-25","conditions":"Multiple Myeloma in Relapse","enrollment":436},{"nctId":"NCT01084252","phase":"PHASE1, PHASE2","title":"Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-05-11","conditions":"Hematological Malignancy","enrollment":351},{"nctId":"NCT02578680","phase":"PHASE3","title":"Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-15","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":616},{"nctId":"NCT04879823","phase":"PHASE3","title":"Post-operative Course of Dexamethasone to Reduce Tonsillectomy Morbidity","status":"TERMINATED","sponsor":"David Chi, MD","startDate":"2021-08-05","conditions":"Adenotonsillectomy, Analgesia, Surgery","enrollment":222},{"nctId":"NCT03530683","phase":"PHASE1","title":"A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-05-14","conditions":"Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia","enrollment":189},{"nctId":"NCT03110562","phase":"PHASE3","title":"Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2017-05-24","conditions":"Multiple Myeloma","enrollment":402},{"nctId":"NCT01843868","phase":"NA","title":"Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP","status":"WITHDRAWN","sponsor":"Australasian Leukaemia and Lymphoma Group","startDate":"2012-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":""},{"nctId":"NCT05574504","phase":"PHASE2","title":"Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy","status":"WITHDRAWN","sponsor":"AdventHealth","startDate":"2023-05-08","conditions":"Metastatic Cancer, Urothelial Carcinoma","enrollment":""},{"nctId":"NCT06486337","phase":"PHASE2","title":"CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-07-10","conditions":"NHL","enrollment":197},{"nctId":"NCT03950674","phase":"PHASE3","title":"Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-02-22","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":40},{"nctId":"NCT06070701","phase":"NA","title":"NOL-Guided Superficial Parasternal Intercostal Plane Block Versus Erector Spinae Plane Block","status":"COMPLETED","sponsor":"Institutul de Urgenţă pentru Boli Cardiovasculare Prof.Dr. C.C. Iliescu","startDate":"2023-06-01","conditions":"Analgesia","enrollment":40},{"nctId":"NCT06350565","phase":"NA","title":"A Clinical Pharmacological Study of Dose Halving of Dexamethasone in Pregnant Women With Preterm Labour With Preterm Birth at Greater Than or Equal to 34 Gestational Weeks (34GW+)","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2024-04-30","conditions":"Respiratory Distress Syndrome of Newborn","enrollment":48},{"nctId":"NCT04840615","phase":"PHASE1","title":"Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-11","conditions":"Mesothelioma","enrollment":2},{"nctId":"NCT06208917","phase":"PHASE3","title":"Ondansetron (ODF) Versus Ondansetron Intravenously for the Prevention of Chemotherapy-induced Nausea and Vomiting Compare in Children","status":"RECRUITING","sponsor":"Yizhuo Zhang","startDate":"2023-07-09","conditions":"Pediatric Solid Tumor, Unspecified, Protocol Specific","enrollment":376},{"nctId":"NCT01858922","phase":"PHASE2","title":"Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2012-12-19","conditions":"Hodgkin Disease","enrollment":40},{"nctId":"NCT02294357","phase":"PHASE2","title":"Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib","status":"TERMINATED","sponsor":"Oncotherapeutics","startDate":"2014-12","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT02623426","phase":"PHASE3","title":"Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2017-03-09","conditions":"Uveitis, Macular Edema","enrollment":194},{"nctId":"NCT02740985","phase":"PHASE1","title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-17","conditions":"Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)","enrollment":313},{"nctId":"NCT02192827","phase":"PHASE3","title":"Use of Dexamethasone in Pediatric Asthma Exacerbations","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2015-04","conditions":"Asthma","enrollment":318},{"nctId":"NCT02490878","phase":"PHASE2","title":"Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2016-04","conditions":"Radionecrosis, Brain Metastases","enrollment":19},{"nctId":"NCT02469519","phase":"PHASE2, PHASE3","title":"Impact of a Booster Course of Antenatal Steroids on Neonatal Outcome in Patients With Premature Rupture of the Membranes","status":"COMPLETED","sponsor":"Pediatrix","startDate":"2016-03-03","conditions":"Premature Birth","enrollment":194},{"nctId":"NCT05647408","phase":"NA","title":"Evaluation of the Bioavailability of Dexamethasone in Healthy Subjects","status":"COMPLETED","sponsor":"Universidad Nacional Autonoma de Mexico","startDate":"2021-11-05","conditions":"Dexamethasone Administration, Intranasal Administration, Inflammation","enrollment":8},{"nctId":"NCT01649947","phase":"PHASE2","title":"Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2011-12-23","conditions":"Non-small Cell Lung Cancer, Advanced Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer","enrollment":32},{"nctId":"NCT01726452","phase":"PHASE3","title":"NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2013-01-24","conditions":"Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Oesophago-gastric Junction, Oesophageal Tumours","enrollment":377},{"nctId":"NCT04265534","phase":"PHASE2","title":"KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC","status":"TERMINATED","sponsor":"Calithera Biosciences, Inc","startDate":"2020-07-24","conditions":"Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung","enrollment":40},{"nctId":"NCT02873806","phase":"PHASE4","title":"Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2013-03","conditions":"Open-angle Glaucoma","enrollment":53},{"nctId":"NCT04382066","phase":"PHASE1","title":"Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19","status":"COMPLETED","sponsor":"PharmaMar","startDate":"2020-05-12","conditions":"COVID-19","enrollment":46},{"nctId":"NCT04640168","phase":"PHASE3","title":"Adaptive COVID-19 Treatment Trial 4 (ACTT-4)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-02","conditions":"COVID-19","enrollment":1010},{"nctId":"NCT05298683","phase":"PHASE2","title":"A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor","status":"UNKNOWN","sponsor":"Hellenic Society of Hematology","startDate":"2022-05","conditions":"Multiple Myeloma, Renal Impairment, Neoplasms, Plasma Cell","enrollment":108},{"nctId":"NCT01847001","phase":"PHASE2","title":"Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"Columbia University","startDate":"2012-10","conditions":"Locally Advanced Malignant Neoplasm, Breast Cancer","enrollment":10},{"nctId":"NCT03050866","phase":"PHASE2","title":"Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2017-02-21","conditions":"Circulating Tumor Cell, Metastatic Prostate Cancer","enrollment":140},{"nctId":"NCT03919734","phase":"","title":"Morbidity and Mortality in Autonomous Cortisol Secretion","status":"COMPLETED","sponsor":"Region Skane","startDate":"2015-09-15","conditions":"Adrenal Incidentaloma, Cortisol Overproduction","enrollment":4596},{"nctId":"NCT04559113","phase":"NA","title":"Methylprednisolone in COVID-19 Patients (Methyl19LGH)","status":"UNKNOWN","sponsor":"Lahore General Hospital","startDate":"2020-05-01","conditions":"SARS-CoV Infection, SARS (Severe Acute Respiratory Syndrome)","enrollment":200},{"nctId":"NCT03133897","phase":"PHASE3","title":"Dexamethasone Versus Prednisone for Asthma Treatment in the Pediatric Inpatient Population; a Feasibility Study","status":"TERMINATED","sponsor":"Children's Hospital of Eastern Ontario","startDate":"2018-03-05","conditions":"Asthma","enrollment":20},{"nctId":"NCT00598169","phase":"PHASE1","title":"Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2007-11","conditions":"Lymphoma","enrollment":23},{"nctId":"NCT02479620","phase":"PHASE2","title":"Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Atherectomy (ATX)-Based Revascularization","status":"UNKNOWN","sponsor":"Mercator MedSystems, Inc.","startDate":"2016-06","conditions":"Chronic Limb Ischemia","enrollment":120},{"nctId":"NCT03094442","phase":"NA","title":"Does Dexamethasone Administration Improve Recovery In Patients Undergoing Minimally Invasive Sacrocolpopexy?","status":"WITHDRAWN","sponsor":"The Cleveland Clinic","startDate":"2016-12","conditions":"Quality of Life, Pelvic Organ Prolapse, Prolapses, Vaginal Vault","enrollment":""},{"nctId":"NCT01697579","phase":"PHASE2","title":"Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-13","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":240},{"nctId":"NCT01191060","phase":"PHASE3","title":"Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2010-10","conditions":"Myeloma","enrollment":700},{"nctId":"NCT01846611","phase":"PHASE3","title":"A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-10-16","conditions":"Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms","enrollment":581},{"nctId":"NCT01215916","phase":"PHASE1","title":"A Phase 1 Study in Patients With Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-02","conditions":"Solid Tumors","enrollment":39},{"nctId":"NCT03803982","phase":"NA","title":"Deep Neuromuscular Relaxation Optimizing Low-Pressure Bariatric Surgery","status":"UNKNOWN","sponsor":"McMaster University","startDate":"2019-01","conditions":"Bariatric Surgery","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Dexamethasone (or equivalent)","genericName":"Dexamethasone (or equivalent)","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm. Used for Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis), Cerebral edema and increased intracranial pressure, Adrenocortical insufficiency.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}